Fritextsökning
Innehållstyper
-
Danish focus on bio chemicals
The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.
-
Danish focus on bio chemicals
The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.
-
Danish focus on bio chemicals
The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.
-
Danish focus on bio chemicals
The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.
-
Danish focus on bio chemicals
The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.
-
Studie: Ny typ av cellterapi kan läka skador på hjärta efter infarkt
I en ny studie har forskare från bland annat Karolinska institutet, Astra Zeneca och Technical University of Munich identifierat en ny typ av cellterapi som har...
-
Hormones make children fat
A new Danish million project will define the connection between hormons and obesity amongst children.
-
Medtech giant separates
Due to the global economic situation, the medtech companies Q-Med and the Palomar Medical Technologies has terminated its international agreement.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Företaget som gör apkoppsvaccin: Vi kan producera 30 miljoner doser
President Investor Relations på Bavarian Nordic, till Life Science Sweden.
-
EU grants project on toxicity of nanomaterials
A multinational research project has have been awarded EUR 3 358 500 from the European Commission to study the hazardous effects of engineered nanomaterials on ...
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Swedish multi competent machine soon launched
The Swedish company Biosensor will launch new equipment able to detect twelve different narcotics and explosives simultaneously.
-
Orexo får ny finanschef
I september börjar Fredrik Järrsten som CFO hos läkemedelsföretaget Orexo. Han kommer även att ingå i ledningsgruppen.
-
Recipharm launches into biologics manufacturing
Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.
-
Sobis giktläkemedel nådde primära mål i fas III
Svenska Sobi och amerikanska partnern Selecta rapporterar övergripande resultat från fas III-studier med giktläkemedlet SEL-212.
-
Pharmiva stärker sin organisation
Pharmiva tillsätter Karolina Akerjordet som ny vice vd och Andrea Mildner som Head of Marketing and Sales.
-
Så ska nya Alzheimerbehandlingen nå patient: ”Vi har några utmaningar”
Stora medicinska framsteg har nyligen gjorts inom Alzheimerfältet - men hur ska de nya behandlingarna nå rätt patienter, och i rätt tid? ”Det kräver att vi tänk...
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Så ska USA satsa på life science
I president Obamas budgetförslag för år 2016 nämns bland annat en satsning mot spridningen av antibiotikaresistens och ett initiativ för individanpassad medicin.
-
Dako appoints new CEO
The Danish cancer therapeutic company Dako has appointed a new CEO after Patrik Dahlén.
-
Immunterapi väcker uppståndelse
En immunterapi mot leukemi har väckt stor uppmärksamhet efter rapporter om att mer än 90 procent av patienterna med terminal cancer blev bättre.
-
Förhandsbesked för Cline
Göteborgsbolaget Cline Scientifics har fått notice of allowance av det amerikanska patentverket.
-
Annika Garnås, LAB
Why are you going to Scanlab+Biotech Forum?
BREAKING